Press release – For immediate release – 5:45 pm CET
Half year Median Technologies liquidity contract statement
Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “the Company”) to TP ICAP (Europe), the following resources were listed in the liquidity account as of December 31, 2024:
- 30,599 shares
- €134,615.99 in cash.
Transactions during the second half 2024:
| BUY | 253,462 shares | 1,060,310.22 EUR | 488 transactions |
| SELL | 259,038 shares | 1,107,913.49 EUR | 452 transactions |
For information, as of June 28th, 2024, the following resources were listed in the liquidity contract:
- 36,135 shares
- €89,040.54 in cash
For information, as of May 4th, 2020, when the new liquidity contract was set up, the following resources were listed in the liquidity account:
- 4,404 shares
- €173,829.64 in cash
The daily transaction table is provided in the appendix to this press release in the pdf version. TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel (ACPR) and the Autorité des Marchés Financiers (AMF).
Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit